Interleukin Deficiency Disorder Patient Responses to COVID-19 Infections
Journal of Advances in Medicine and Medical Research,
Background: The chemokine, cytokine interleukin deficiency disorder defines the immune deficiency disease of fibromyalgia and a reduced ability to produce IL-6 and IL-8. Recent research has demonstrated improved outcomes in COVID-19 infections treated with IL-6 antagonists.9 These fibromyalgia cytokine deficient patients were screened for COVID-19 infections and associated morbidity and mortality rates.
Methods: Two cohorts of FM/a test positive fibromyalgia patients were evaluated. Initially, 4,631 patients were screened to determine the occurrence of known COVID-19 infections. Subsequently, 2,195 FM/a test positive patients underwent COVID-19 antibody testing.
Results: A total of 7,375 fibromyalgia patients were screened for the occurrence of COVID-19 infections. Of these, 4,631 individuals responded to an email-based inquiry to determine the occurrence of documented COVID-19 infections. Only 10 reported having symptoms consistent with and were diagnosed with COVID-19 by a healthcare professional, making for an incidence of .22%. Another 2,195 fibromyalgia patients completed health questionnaires and COVID-19 antibody testing and 82 had evidence of COVID-19 antibodies with 42 exhibiting symptoms and confirmed diagnoses. Of the remaining, 23 were asymptomatic. There were no deaths and only 1 hospitalization in this group.
Conclusion: Individuals with FM/a test positive fibromyalgia have a reduced ability to produce IL-6 and IL-8 which play significant roles in the cytokine storm complications associated with COVID-19 infections. When screened for evidence of past COVID-19 infections, these patients experienced an extremely low incidence of COVID-19 infections based upon antibody testing, there were no mortalities and the level of morbidity was significantly below what has been reported in general populations.
How to Cite
Wallace D, et al. Cytokine and chemokine profiles in Fibromyalgia, rheumatoid arthritis and systemic lupus erythe- matosus: A potentially useful tool in differential diagnosis. Rheumatology International; 2015.
Zeng H, et al. Longitudinal profile of laboratory parameters and their application in the prediction for fatal outcome among patients infected with SARS-COV-2: A Retrospective Cohort Study. Clinical Infectious Diseases; 2020
Mahmudpour M, et al. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020.133.
Ghazavi A, et al. Cytokine profile and disease severity in patients with COVID-19. Cytokine. 2020;137
Mc Elvaney OJ, et al. A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. E Bio Medicine 2020;61.
Nagant C, et al. A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer. International Journal of Infectious Diseases; 2020.
Noroozi R, et al. Altered cytokine levels and immune responses in patients with SARS-COV-2 Infection and Related Conditions. Cytokine. 2020;133.
REMAP-CAP Investigators: Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. NEJM; 2021.
Abstract View: 5757 times
PDF Download: 487 times